Bloomage Launches MitoPQQ™ and Presents Hyaluronic Acid Research at IFT FIRST Expo 2024
CHICAGO, July 16, 2024 /PRNewswire/ -- Bloomage, a global leader specializing in hyaluronic acid and other bioactive substance innovations, launched its new product - MitoPQQ™ and presented its latest hyaluronic acid research at the 2024 IFT FIRST expo, one of the largest gatherings of global experts in the food science industry. Focused on skin beauty,emotional & sleep health, joint...
Seegene Showcases HPV Diagnostic Kits and PCR Technology at AOGIN 2024
Showcases Allplex™ HPV products designed to test for 14 high-risk HPV genotypes Advocates HPV testing for early diagnosis and prevention of cervical cancer Aims to accelerate the widespread adoption of syndromic PCR testing to create "a world free from all diseases" SEOUL, South Korea, July 16, 2024 /PRNewswire/ -- Seegene Inc. (KQ096530), a leading...
SPI Pharma, Inc. and Inimmune, Corp. Partner to Develop and Commercialize Innovative Vaccine Adjuvant Systems
WILMINGTON, Del., July 16, 2024 /PRNewswire/ -- SPI Pharma, Inc. a global leader in biopharmaceutical excipient and adjuvant systems, and Inimmune, Corp., a pioneering biotechnology company specializing in the discovery and development of innate immune modulators, announce an agreement in principle to create a strategic collaboration to develop and commercialize advanced...
IMG Welcomes Susan Yates as Chief Customer Officer
INDIANAPOLIS, July 16, 2024 /PRNewswire/ -- IMG (International Medical Group), an award-winning global insurance benefits and assistance services company, is pleased to introduce Susan Yates as the company's new Chief Customer Officer. Yates joins the IMG team with more than 25 years of experience in the insurance and global assistance industries. "I am...
Shaping the Future: Forum 30, The MPHO Safety and Traceability Summit in Rome
REDLANDS, Calif., July 16, 2024 /PRNewswire/ -- The International Council for Commonality in Blood Banking Automation ("ICCBBA"), in partnership with the Italian national competent authorities for blood Centro Nazionale Sangue ("CNS") and cells/tissues Centro Nazionale Trapianti ("CNT"), will be hosting Forum 30 The MPHO Safety and Traceability Summit on 14-15 November 2024. The Forum 30 Summit is set to provide a transformative...
Yoshitsu Co., Ltd Reports Fiscal Year 2024 Financial Results
TOKYO, July 16, 2024 /PRNewswire/ -- Yoshitsu Co., Ltd ("Yoshitsu" or the "Company") (Nasdaq: TKLF), a retailer and wholesaler of Japanese beauty and health products, sundry products, luxury products, electronic products, as well as other products in Hong Kong, Japan, North America, and the United Kingdom, today announced its financial results for the fiscal year 2024 ended March 31,...
Sanyou Bio Collaborates on ADC Drug Development Entering Phase I Clinical Trials
SHANGHAI, July 16, 2024 /PRNewswire/ -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "Sanyou Bio") has recently announced a significant milestone in collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963, hereinafter referred to as "Huadong Medicine"). The jointly developed ADC drug, designated as project number SYHD001, has successfully...
Metabolon Expands Library to Include 70 Pesticides, Advancing Human Exposome Insights through Metabolomics
MORRISVILLE, N.C., July 16, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced the expansion of its metabolite library to include 70 pesticides, strengthening the company's ability to provide comprehensive environmental...
3rd AUTISM EXPO Concludes Successfully with Celebration and Unity
SEOUL, South Korea, July 16, 2024 /PRNewswire/ -- The 3rd AUTISM EXPO 2024 concluded on a high note, featuring a wide range of exhibits and diverse events that attracted enthusiastic participation from individuals with developmental disabilities, their families, and related organizations. 3rd AUTISM EXPO Concludes Successfully...
Biosyngen’s BRG01 enters Phase II clinical trial, a first-in-kind autologous EBV-Specific CAR-T Therapy for Solid Tumors on Recurrent/Metastatic Nasopharyngeal Carcinoma
SINGAPORE, July 16, 2024 /PRNewswire/ -- Biosyngen, a leading biotechnology company focused on the development of innovative cell therapies, recently announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China has approved the initiation of a pivotal Phase ll clinical trial evaluating BRG01, the company's autologous Epstein-Barr virus (EBV) specific chimeric antigen...
